Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Highlights
- ➤$129.4 million cash and investments; runway expected through March 31, 2028
- ➤$6.2 million Q3 net loss, or $0.72 per share, versus $3.4 million
- ➤ALXN1840 NDA rolling submission on track for completion within several weeks
- ➤Only 47% of treatment-experienced patients met guideline-recommended copper targets
- ➤ALXN1840 showed neutral molybdenum balance and no toxicity over six years
WILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2026 financial results and provided business updates.
On November 8, 2026, Monopar presented baseline findings from the Phase 3 FoCus study of ALXN1840 (tiomolibdate choline, TMC), the largest randomized controlled trial ever conducted in Wilson disease, characterizing residual disease burden in treatment-experienced patients at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026. Baseline rates in treatment-experienced and treatment-naïve patients were 39% and 30% for cirrhosis, 79% and 83% for neurologic symptoms, and 75% and 70% for psychiatric symptoms, respectively. Among evaluable patients, 73% had at least two of these manifestations. Only 47% of treatment-experienced patients were within the guideline-recommended copper target range. Among patients receiving standard-of-care therapy for more than 12 months, 31% had 24-hour urinary copper excretion above that range.
Get started
Create a free account to read the full story.